









Markets
/
Stocks
/
nasdaq-aktx
/

Akari Therapeutics PLC

AKTX

0.685USD

-0.134-16.40%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

22.36MMarket Cap

LossP/E TTM



Akari Therapeutics PLC

0.685

-0.134-16.40%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Akari Therapeutics PLC

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Akari Therapeutics PLC's Score

Industry at a Glance

Industry Ranking

131 / 173

Overall Ranking

491 / 4682

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

4.533

Target Price

+525.29%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Akari Therapeutics PLC Highlights

StrengthsRisks

Akari Therapeutics, Plc is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. The Company is engaged in the development of antibody drug conjugates (ADCs) and advanced therapies for autoimmune and inflammatory diseases, including geographic atrophy (GA). Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. The Company is conducting pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). It is conducting a phase III clinical trial in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The Company's pipeline also includes the PH-1 ADC Platform for oncology, PHP-303 program for genetic disease, liver disease and inflammation, specifically for Alpha-1 antitrypsin deficiency (AATD) and acute respiratory distress syndrome (ARDS), including COVID-19.

Undervalued

The company’s latest PE is -3.31, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 562.62K shares, increasing 21.98% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 17.41K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Pharmaceuticals industry's average is 7.77.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Akari Therapeutics PLC's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 7.49, which is higher than the Pharmaceuticals industry's average of 7.19. Its current P/E ratio is -3.31, which is -113.07% below the recent high of 0.43 and -47.30% above the recent low of -4.88.

Score

Industry at a Glance

Previous score

7.49

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 131/173

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Akari Therapeutics PLC is 5.00, with a high of 7.00 and a low of 1.60.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

4.533

Target Price

+452.85%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Akari Therapeutics PLC

AKTX

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 4.45, which is lower than the Pharmaceuticals industry's average of 7.05. Sideways: Currently, the stock price is trading between the resistance level at 1.03 and the support level at 0.64, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.42

Change

0.03

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.008

Sell

RSI(14)

39.363

Neutral

STOCH(KDJ)(9,3,3)

39.787

Neutral

ATR(14)

0.068

High Vlolatility

CCI(14)

-193.929

Sell

Williams %R

75.366

Sell

TRIX(12,20)

-0.911

Sell

StochRSI(14)

3.923

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.742

Sell

MA10

0.751

Sell

MA20

0.801

Sell

MA50

0.841

Sell

MA100

0.957

Sell

MA200

1.083

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.59. The latest institutional shareholding proportion is 1.72%, representing a quarter-over-quarter decrease of 95.16%. The largest institutional shareholder is James Simons, holding a total of 17.41K shares, representing 0.05% of shares outstanding, with 44.78% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Huh (Hoyoung)

4.70M

+23.48%

Patel (Samir Rashmikant)

2.66M

+56.14%

Prudo-Chlebosz (Raymond)

2.46M

+22.20%

Theofilos (Charles Steve)

1.06M

Gaslightwala (Abizer)

262.71K

+8.69%

Sabby Management, LLC

179.78K

Palo Alto Investors LP

146.02K

Hightower Advisors, LLC

79.24K

Omnia Family Wealth, LLC

62.69K

-28.46%

Bazemore (Robert B)

44.64K

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Pharmaceuticals industry's average is 5.11. The company's beta value is 0.34. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.